TY - JOUR AU - Szekanecz, Zoltán AU - Szamosi, Szilvia AU - Benkő, Szilvia AU - Szűcs, Gabriella TI - Monogénesen öröklődő és szerzett autoinflammatoricus betegségek JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 18 SP - 683 EP - 697 PG - 15 SN - 0030-6002 UR - https://m2.mtmt.hu/api/publication/34797501 ID - 34797501 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Simon, Diána AU - Kacsándi, Dorottya AU - Karancsiné Pusztai, Anita AU - Soós, Boglárka AU - Végh, Edit AU - Kerekes, György AU - Czókolyová, Monika AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Prohászka, Zoltán AU - Németh, Péter AU - Berki, Tímea AU - Szekanecz, Zoltán TI - Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 6 PG - 14 SN - 1661-6596 DO - 10.3390/ijms25063429 UR - https://m2.mtmt.hu/api/publication/34745209 ID - 34745209 N1 - * Megosztott szerzőség AB - Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (p < 0.05). We also found associations between anti-TOPO-F4 IgG and anti-Hsp60 IgG (p < 0.05). Baseline nAAb levels or nAAb level changes might determine changes in CRP, disease activity, FMD, PWV, and ccIMT over time (p < 0.05). The interplay between arthritis and inflammatory atherosclerosis, as well as the effects of anti-TNF biologics on these pathologies, might independently involve nAAbs. LA - English DB - MTMT ER - TY - JOUR AU - Kerekes, György AU - Bodoki, Levente AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Tajti, Gábor AU - Katkó, Mónika AU - Végh, Edit AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Horváth, Ágnes AU - Soós, B. AU - Szamosi, Szilvia AU - Hascsi, Z. AU - Harangi, Mariann AU - Panyi, György AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - AB0237 EFFECTS OF ONE-YEAR TOFACITINIB THERAPY ON ANGIOGENIC BIOMARKERS IN RHEUMATOID ARTHRITIS JF - ANNALS OF THE RHEUMATIC DISEASES J2 - ANN RHEUM DIS VL - 82 PY - 2023 IS - S1 SP - 1303 EP - 1303 PG - 1 SN - 0003-4967 DO - 10.1136/annrheumdis-2023-eular.2331 UR - https://m2.mtmt.hu/api/publication/34775337 ID - 34775337 LA - English DB - MTMT ER - TY - JOUR AU - Spiera, Robert F. AU - Unizony, Sebastian AU - Warrington, Kenneth J. AU - Sloane, Jennifer AU - Giannelou, Angeliki AU - Nivens, Michael C. AU - Akinlade, Bolanle AU - Wong, Wanling AU - Bhore, Rafia AU - Lin, Yong AU - Buttgereit, Frank AU - Devauchelle-Pensec, Valerie AU - Rubbert-Roth, Andrea AU - Yancopoulos, George D. AU - Marrache, Frederic AU - Patel, Naimish AU - Dasgupta, Bhaskar ED - Szűcs, Gabriella / Collaborator ED - Pethő, Zsófia / Collaborator ED - Soós, Boglárka / Collaborator ED - Szamosi, Szilvia / Collaborator ED - Végh, Edit / Collaborator TI - Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 389 PY - 2023 IS - 14 SP - 1263 EP - 1272 PG - 10 SN - 0028-4793 DO - 10.1056/NEJMoa2303452 UR - https://m2.mtmt.hu/api/publication/34391690 ID - 34391690 LA - English DB - MTMT ER - TY - JOUR AU - Szekanecz, Zoltán AU - Vokó, Zoltán AU - Surján, Orsolya AU - Rákóczi, Éva AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Szekanecz, Éva AU - Müller, Cecília AU - Kiss, Zoltán TI - Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 14 PY - 2023 PG - 8 SN - 1664-3224 DO - 10.3389/fimmu.2023.1247129 UR - https://m2.mtmt.hu/api/publication/34250233 ID - 34250233 N1 - * Megosztott szerzőség AB - Introduction In Hungary, the HUN-VE 3 study determined the comparative effectiveness of various primary and booster vaccination strategies during the Delta COVID-19 wave. That study included more than 8 million 18-100-year-old individuals from the beginning of the pandemic. Immunocompromised (IC) individuals have increased risk for COVID-19 and disease course might be more severe in them. In this study, we wished to estimate the risk of SARS-CoV-2 infection and COVID-19 related death in IC individuals compared to healthy ones and the effectiveness of the BNT162b2 vaccine by reassessing HUN-VE 3 data. Patients and methods Among the 8,087,988 individuals undergoing follow-up from the onset of the pandemic in the HUN-VE 3 cohort, we selected all the 263,116 patients with a diagnosis corresponding with IC and 6,128,518 controls from the second wave, before vaccinations started. The IC state was defined as two occurrences of corresponding ICD-10 codes in outpatient or inpatient claims data since 1 January, 2013. The control group included patients without chronic diseases. The data about vaccination, SARS-CoV-2 infection and COVID-19 related death were obtained from the National Public Health Center (NPHC) during the Delta wave. Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the National Public Health Center (NPHC). Results Out of the 263,116 IC patients 12,055 patients (4.58%) and out of the 6,128,518 healthy controls 202,163 (3.30%) acquired SARS-CoV-2 infection. Altogether 436 IC patients and 2141 healthy controls died in relation to COVID-19. The crude incidence rate ratio (IRR) of SARS-CoV-2 infection was 1.40 (95%CI: 1.37-1.42) comparing IC patients to healthy controls. The crude mortality rate ratio was 4.75 (95%CI: 4.28-5.27). With respect to SARS-CoV-2 infection, interestingly, the BNT162b2 vaccine was more effective in IC patients compared to controls. Primary vaccine effectiveness (VE) was higher in IC patients compared to controls and the booster restored VE after waning. VE regarding COVID-19 related death was less in IC patients compared to healthy individuals. Booster vaccination increased VE against COVID-19-related death in both IC patients and healthy controls. Conclusion There is increased risk of SARS-CoV-2 infection and COVID-19 related mortality in IC patient. Moreover, booster vaccination using BNT162b2 might restore impaired VE in these individuals. LA - English DB - MTMT ER - TY - JOUR AU - Kerekes, György AU - Czókolyová, Monika AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Tajti, Gábor AU - Katkó, Mónika AU - Végh, Edit AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Horváth, Ágnes AU - Soós, Boglárka AU - Szamosi, Szilvia AU - Hascsi, Zsolt AU - Harangi, Mariann AU - Hodosi, Katalin AU - Panyi, György AU - Seres, Tamás AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis JF - RHEUMATOLOGY (UNITED KINGDOM) J2 - RHEUMATOLOGY VL - 62 PY - 2023 IS - SI3 SP - SI304 EP - SI312 SN - 1462-0324 DO - 10.1093/rheumatology/kead502 UR - https://m2.mtmt.hu/api/publication/34215318 ID - 34215318 LA - English DB - MTMT ER - TY - JOUR AU - Kacsándi, Dorottya AU - Fagyas, Miklós AU - Horváth, Ágnes AU - Végh, Edit AU - Pusztai, Anita AU - Czókolyová, Monika AU - Soós, Boglárka AU - Szabó, Attila Ádám AU - Hamar, Attila AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Kerekes, György AU - Hodosi, Katalin AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Papp, Zoltán AU - Szekanecz, Zoltán TI - Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 10 PY - 2023 SN - 2296-858X DO - 10.3389/fmed.2023.1226760 UR - https://m2.mtmt.hu/api/publication/34185575 ID - 34185575 LA - English DB - MTMT ER - TY - JOUR AU - Végh, Edit AU - Bodnár, Nóra AU - Szamosi, Szilvia AU - Szántó, Sándor Zoltán AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - Gyulladásos bélbetegségekhez társuló spondylarthritis JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 SP - 73 EP - 81 PG - 9 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34047238 ID - 34047238 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szamosi, Szilvia AU - Bodnár, Nóra AU - Bodoki, Levente AU - Gyetkó, Zsuzsanna AU - Horváth, Ágnes AU - Pethő, Zsófia AU - Tari, Dóra AU - Szekanecz, Zoltán AU - Szűcs, Gabriella TI - A szisztémás lupus erythematosus immunopatogenezise JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 15 PY - 2023 IS - 1 SP - 34 EP - 46 PG - 13 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/33724256 ID - 33724256 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Soos, Boglarka AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Czókolyová, Monika AU - Végh, Edit AU - Szamosi, Szilvia AU - Pethő, Zsófia AU - Gulyás, Katalin AU - Kerekes, György AU - Szántó, Sándor Zoltán AU - Szűcs, Gabriella AU - Christians, Uwe AU - Klawitter, Jelena AU - Seres, Tamas AU - Szekanecz, Zoltán TI - Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 9 PY - 2022 PG - 16 SN - 2296-858X DO - 10.3389/fmed.2022.1011734 UR - https://m2.mtmt.hu/api/publication/33457576 ID - 33457576 N1 - Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Intensive Care Unit, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Department of Sports Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States Export Date: 4 January 2023 Correspondence Address: Szekanecz, Z.; Department of Rheumatology, Hungary; email: szekanecz.zoltan@med.unideb.hu AB - IntroductionRheumatoid arthritis (RA) has been associated with changes in lipid, arginine and NO metabolism with increased cardiovascular (CV) risk. The aim of this study is to evaluate the effect of tofacitinib, a Janus kinase (JAK) inhibitor, on arginine and methionine metabolism in correlation with inflammation, functional and pathological vascular changes during one-year treatment of patients with RA. Materials and methodsThirty RA patients with active disease were treated with either 5 mg bid or 10 mg bid tofacitinib for 12 months. We determined DAS28, CRP, IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) levels. We assessed brachial artery flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) by ultrasound at baseline and after 6 and 12 months. We also determined plasma L-arginine, L-citrulline, L-ornithine, inducible nitric oxide synthase (iNOS), asymmetric (ADMA) and symmetric dimethylarginine (SDMA), L-N-monomethyl-arginine (L-NMMA), cysteine, homocysteine, and methionine levels at these time points. ResultsTwenty-six patients (13 on each arm) completed the study. CRP, ESR and DAS28 decreased significantly during one-year treatment with tofacitinib. Arginine and ADMA showed a negative univariate correlation with CRP but not with FMD, PWV or IMT. Tofacitinib at 10 mg bid significantly increased L-arginine, L-ornithine, iNOS and methionine levels after 12 months. ADMA and SDMA levels did not change in our study. Methionine showed negative correlation with FMD at baseline and positive correlation with PWV after 12 months. No change was observed in FMD and PWV but a significant increase was measured in IMT at 6 and 12 months. Multivariate analysis indicated variable correlations of L-arginine, L-citrulline, ADMA, L-NMMA, homocysteine and methionine with DAS28, CRP, ESR and RF but not with anti-CCP after one-year treatment. With respect to vascular pathophysiology, only PWV and methionine correlated with each other. ConclusionOne-year tofacitinib treatment suppressed systemic inflammation and improved functional status in RA. FMD, PWV have not been affected by one-year tofacitinib treatment., while IMT increased further despite treatment. Increased arginine and methionine might contribute to the anti-inflammatory effects of tofacitinib. Increased arginine availability with no changing ADMA may protect FMD and PWV from deterioration. The increase of IMT in the anti-inflammatory environment cannot be explained by arginine or methionine metabolism in this study. LA - English DB - MTMT ER -